Megadalton-sized Dityrosine Aggregates of α-Synuclein Retain High Degrees of Structural Disorder and Internal Dynamics.


Journal

Journal of molecular biology
ISSN: 1089-8638
Titre abrégé: J Mol Biol
Pays: Netherlands
ID NLM: 2985088R

Informations de publication

Date de publication:
04 12 2020
Historique:
received: 12 09 2020
revised: 15 10 2020
accepted: 15 10 2020
pubmed: 20 11 2020
medline: 5 3 2021
entrez: 19 11 2020
Statut: ppublish

Résumé

Heterogeneous aggregates of the human protein α-synuclein (αSyn) are abundantly found in Lewy body inclusions of Parkinson's disease patients. While structural information on classical αSyn amyloid fibrils is available, little is known about the conformational properties of disease-relevant, non-canonical aggregates. Here, we analyze the structural and dynamic properties of megadalton-sized dityrosine adducts of αSyn that form in the presence of reactive oxygen species and cytochrome c, a proapoptotic peroxidase that is released from mitochondria during sustained oxidative stress. In contrast to canonical cross-β amyloids, these aggregates retain high degrees of internal dynamics, which enables their characterization by solution-state NMR spectroscopy. We find that intermolecular dityrosine crosslinks restrict αSyn motions only locally whereas large segments of concatenated molecules remain flexible and disordered. Indistinguishable aggregates form in crowded in vitro solutions and in complex environments of mammalian cell lysates, where relative amounts of free reactive oxygen species, rather than cytochrome c, are rate limiting. We further establish that dityrosine adducts inhibit classical amyloid formation by maintaining αSyn in its monomeric form and that they are non-cytotoxic despite retaining basic membrane-binding properties. Our results suggest that oxidative αSyn aggregation scavenges cytochrome c's activity into the formation of amorphous, high molecular-weight structures that may contribute to the structural diversity of Lewy body deposits.

Identifiants

pubmed: 33211011
pii: S0022-2836(20)30598-2
doi: 10.1016/j.jmb.2020.10.023
pmc: PMC7779668
pii:
doi:

Substances chimiques

Amyloid 0
Amyloid beta-Peptides 0
Protein Aggregates 0
Reactive Oxygen Species 0
SNCA protein, human 0
alpha-Synuclein 0
Tyrosine 42HK56048U
Cytochromes c 9007-43-6
dityrosine CJ9XG8HS20

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

166689

Subventions

Organisme : Wellcome Trust
ID : 108504
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 103139
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M02492X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203149
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00024/6
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no competing interests.

Références

J Am Chem Soc. 2010 May 19;132(19):6636-7
pubmed: 20423081
Nature. 2016 Feb 4;530(7588):45-50
pubmed: 26808899
J Mol Cell Biol. 2011 Aug;3(4):239-49
pubmed: 21733982
Neurobiol Dis. 2019 Apr;124:248-262
pubmed: 30472299
NPJ Parkinsons Dis. 2019 Jun 27;5:12
pubmed: 31263746
Nat Commun. 2019 Dec 4;10(1):5535
pubmed: 31797870
Nat Commun. 2018 Jun 12;9(1):2293
pubmed: 29895861
Nature. 2020 Sep;585(7825):464-469
pubmed: 32461689
Acta Neuropathol. 2019 Nov;138(5):681-704
pubmed: 31006067
Nat Commun. 2018 Feb 26;9(1):817
pubmed: 29483518
Intrinsically Disord Proteins. 2015 Oct 19;3(1):e1071302
pubmed: 28232892
Neurotox Res. 2008 May-Jun;13(3-4):221-30
pubmed: 18522901
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4971-4982
pubmed: 32075919
Neurosci Lett. 2019 Sep 14;709:134316
pubmed: 31170426
Nat Commun. 2016 Jan 25;7:10251
pubmed: 26807843
J Neurochem. 2013 May;125(4):491-511
pubmed: 23452040
Front Neurosci. 2018 Jun 07;12:388
pubmed: 29930495
Oxid Med Cell Longev. 2020 Apr 17;2020:6813405
pubmed: 32377304
Hum Mol Genet. 2019 Jun 15;28(12):2001-2013
pubmed: 30753527
Front Mol Neurosci. 2014 May 13;7:42
pubmed: 24860424
Mol Neurobiol. 2020 Jul;57(7):2959-2980
pubmed: 32445085
Anal Chem. 2017 Jun 6;89(11):6136-6145
pubmed: 28453255
Free Radic Biol Med. 2012 Aug 15;53(4):1004-15
pubmed: 22771470
Neurobiol Dis. 2020 Jul;141:104876
pubmed: 32339655
ACS Chem Neurosci. 2014 Dec 17;5(12):1203-8
pubmed: 25320964
J Biol Chem. 2000 Jun 16;275(24):18344-9
pubmed: 10747881
J Parkinsons Dis. 2016;6(1):39-51
pubmed: 27003784
J Biol Chem. 1999 Oct 8;274(41):28849-52
pubmed: 10506125
J Biol Chem. 2014 Feb 7;289(6):3652-65
pubmed: 24338013
J Am Chem Soc. 2013 Feb 27;135(8):2943-6
pubmed: 23398174
Sci Rep. 2016 Dec 16;6:39171
pubmed: 27982082
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73
pubmed: 9600990
J Mol Biol. 2017 Oct 13;429(20):3018-3030
pubmed: 28918091
ACS Chem Neurosci. 2019 Mar 20;10(3):1300-1310
pubmed: 30620180
J Biol Chem. 2003 Jul 18;278(29):27230-40
pubmed: 12857790
ACS Chem Neurosci. 2019 Feb 20;10(2):777-782
pubmed: 30183251
Neurobiol Dis. 2014 Oct;70:149-61
pubmed: 24983211
Nature. 2020 Jan;577(7788):127-132
pubmed: 31802003
Biochemistry. 2008 Dec 23;47(51):13604-9
pubmed: 19049426
Biochem Soc Trans. 2018 Aug 20;46(4):829-842
pubmed: 29986938
Anal Biochem. 1996 Nov 15;242(2):202-13
pubmed: 8937563
J Biol Chem. 2009 Jun 5;284(23):15951-69
pubmed: 19351880
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1661-8
pubmed: 16449387
Science. 2010 Sep 24;329(5999):1663-7
pubmed: 20798282
J Neurochem. 2019 Sep;150(5):522-534
pubmed: 31254394
Chem Rev. 2017 Nov 8;117(21):13382-13460
pubmed: 29027792
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
Front Genet. 2014 Nov 07;5:382
pubmed: 25426138
Nat Commun. 2014 May 29;5:3827
pubmed: 24871041
Curr Opin Neurobiol. 2020 Apr;61:89-95
pubmed: 32112991
Mol Neurodegener. 2009 Jun 05;4:24
pubmed: 19500376
J Mol Biol. 2001 Apr 6;307(4):1061-73
pubmed: 11286556
Nature. 2002 Apr 4;416(6880):507-11
pubmed: 11932737
Nat Rev Mol Cell Biol. 2020 Feb;21(2):85-100
pubmed: 31636403
Trends Neurosci. 2019 Feb;42(2):140-149
pubmed: 30509690
Nature. 2020 Feb;578(7794):273-277
pubmed: 32025029
J Neurochem. 2002 Jul;82(2):305-15
pubmed: 12124431
Mol Neurodegener. 2016 Nov 24;11(1):70
pubmed: 27884192
Science. 2017 Dec 15;358(6369):1440-1443
pubmed: 29242346
Methods Enzymol. 1977;47:431-42
pubmed: 22021
Prog Brain Res. 2010;183:115-45
pubmed: 20696318
Curr Opin Struct Biol. 2018 Feb;48:49-57
pubmed: 29100107
J Mol Biol. 2009 Jul 24;390(4):775-90
pubmed: 19481095

Auteurs

Silvia Verzini (S)

Leibniz Institute of Molecular Pharmacology (FMP-Berlin), Robert-Rössle Strasse 10, 13125 Berlin, Germany.

Maliha Shah (M)

Neuroproteomics Laboratory, Max Delbrück Centre for Molecular Medicine (MDC-Berlin), Robert-Rössle Strasse 10, 13125 Berlin, Germany.

Francois-Xavier Theillet (FX)

Leibniz Institute of Molecular Pharmacology (FMP-Berlin), Robert-Rössle Strasse 10, 13125 Berlin, Germany.

Adam Belsom (A)

Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom.

Jan Bieschke (J)

Neuroproteomics Laboratory, Max Delbrück Centre for Molecular Medicine (MDC-Berlin), Robert-Rössle Strasse 10, 13125 Berlin, Germany.

Erich E Wanker (EE)

Neuroproteomics Laboratory, Max Delbrück Centre for Molecular Medicine (MDC-Berlin), Robert-Rössle Strasse 10, 13125 Berlin, Germany.

Juri Rappsilber (J)

Wellcome Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3BF, United Kingdom.

Andres Binolfi (A)

Leibniz Institute of Molecular Pharmacology (FMP-Berlin), Robert-Rössle Strasse 10, 13125 Berlin, Germany.

Philipp Selenko (P)

Leibniz Institute of Molecular Pharmacology (FMP-Berlin), Robert-Rössle Strasse 10, 13125 Berlin, Germany. Electronic address: philipp.selenko@weizmann.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH